Loading...
Loading...
LGVN| Name | Value |
|---|---|
| Revenues | 279.0K |
| Cost of Revenue | 203.0K |
| Gross Profit | 76.0K |
| Operating Expense | 4,792.0K |
| Operating I/L | -4,716.0K |
| Other Income/Expense | 69.0K |
| Interest Income | 0.0K |
| Pretax | -4,647.0K |
| Income Tax Expense | -69.0K |
| Net Income/Loss | -4,578.0K |
Longeveron Inc. is a clinical stage biotechnology company specializing in the development of cellular therapies for aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy derived from bone marrow of young healthy adult donors. The company generates revenue through conducting Phase 1 and 2 clinical trials for various indications including aging frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
